<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p160" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_160{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_160{left:306px;bottom:30px;}
#t3_160{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_160{left:346px;bottom:30px;}
#t5_160{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_160{left:517px;bottom:30px;}
#t7_160{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_160{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_160{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_160{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_160{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:0.05px;}
#tc_160{left:290px;bottom:785px;letter-spacing:-0.01px;}
#td_160{left:313px;bottom:777px;letter-spacing:0.1px;word-spacing:0.08px;}
#te_160{left:35px;bottom:754px;letter-spacing:0.05px;word-spacing:0.13px;}
#tf_160{left:35px;bottom:731px;letter-spacing:0.1px;word-spacing:-1.02px;}
#tg_160{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:0.08px;}
#th_160{left:35px;bottom:684px;letter-spacing:-0.08px;}
#ti_160{left:116px;bottom:692px;letter-spacing:-0.01px;}
#tj_160{left:35px;bottom:647px;letter-spacing:-0.14px;word-spacing:0.57px;}
#tk_160{left:35px;bottom:622px;letter-spacing:0.13px;word-spacing:0.06px;}
#tl_160{left:35px;bottom:599px;letter-spacing:0.3px;word-spacing:-1.35px;}
#tm_160{left:149px;bottom:599px;letter-spacing:0.25px;word-spacing:-0.05px;}
#tn_160{left:380px;bottom:599px;letter-spacing:0.19px;}
#to_160{left:35px;bottom:575px;letter-spacing:0.12px;word-spacing:0.06px;}
#tp_160{left:35px;bottom:552px;letter-spacing:0.15px;word-spacing:0.04px;}
#tq_160{left:35px;bottom:529px;letter-spacing:0.06px;word-spacing:0.12px;}
#tr_160{left:35px;bottom:507px;word-spacing:0.19px;}
#ts_160{left:35px;bottom:484px;letter-spacing:0.14px;word-spacing:-0.36px;}
#tt_160{left:35px;bottom:460px;letter-spacing:0.08px;word-spacing:-0.72px;}
#tu_160{left:266px;bottom:468px;}
#tv_160{left:310px;bottom:460px;letter-spacing:-0.03px;word-spacing:-0.03px;}
#tw_160{left:35px;bottom:437px;letter-spacing:0.1px;word-spacing:0.08px;}
#tx_160{left:35px;bottom:414px;letter-spacing:0.03px;word-spacing:-0.78px;}
#ty_160{left:35px;bottom:391px;letter-spacing:0.14px;word-spacing:0.05px;}
#tz_160{left:35px;bottom:368px;letter-spacing:0.15px;word-spacing:0.03px;}
#t10_160{left:35px;bottom:344px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t11_160{left:35px;bottom:321px;letter-spacing:0.13px;word-spacing:0.05px;}
#t12_160{left:35px;bottom:281px;letter-spacing:0.18px;word-spacing:0.01px;}
#t13_160{left:35px;bottom:261px;letter-spacing:0.38px;word-spacing:-0.18px;}
#t14_160{left:35px;bottom:232px;letter-spacing:0.07px;word-spacing:0.11px;}
#t15_160{left:35px;bottom:209px;letter-spacing:0.05px;word-spacing:0.14px;}
#t16_160{left:35px;bottom:185px;letter-spacing:0.07px;word-spacing:0.12px;}
#t17_160{left:35px;bottom:162px;letter-spacing:0.13px;word-spacing:0.07px;}
#t18_160{left:35px;bottom:139px;letter-spacing:0.08px;word-spacing:-0.19px;}
#t19_160{left:35px;bottom:116px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1a_160{left:35px;bottom:93px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1b_160{left:35px;bottom:69px;letter-spacing:0.07px;word-spacing:-0.5px;}
#t1c_160{left:618px;bottom:777px;letter-spacing:0.14px;word-spacing:-0.26px;}
#t1d_160{left:618px;bottom:754px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1e_160{left:618px;bottom:731px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1f_160{left:618px;bottom:707px;letter-spacing:0.19px;word-spacing:0.01px;}
#t1g_160{left:930px;bottom:707px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1h_160{left:618px;bottom:684px;letter-spacing:0.08px;word-spacing:-1.12px;}
#t1i_160{left:618px;bottom:661px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t1j_160{left:831px;bottom:661px;}
#t1k_160{left:618px;bottom:624px;letter-spacing:-0.11px;word-spacing:0.54px;}
#t1l_160{left:618px;bottom:599px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t1m_160{left:754px;bottom:606px;letter-spacing:0.06px;}
#t1n_160{left:821px;bottom:599px;letter-spacing:-0.14px;word-spacing:0.33px;}
#t1o_160{left:963px;bottom:606px;}
#t1p_160{left:1008px;bottom:599px;letter-spacing:0.14px;word-spacing:0.06px;}
#t1q_160{left:618px;bottom:575px;letter-spacing:0.06px;word-spacing:-0.73px;}
#t1r_160{left:618px;bottom:552px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1s_160{left:618px;bottom:529px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1t_160{left:618px;bottom:507px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t1u_160{left:618px;bottom:467px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1v_160{left:618px;bottom:443px;letter-spacing:0.08px;word-spacing:-0.42px;}
#t1w_160{left:618px;bottom:420px;letter-spacing:0.19px;}
#t1x_160{left:618px;bottom:397px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1y_160{left:760px;bottom:404px;}
#t1z_160{left:771px;bottom:397px;letter-spacing:0.27px;word-spacing:-0.08px;}
#t20_160{left:1101px;bottom:404px;letter-spacing:0.1px;}
#t21_160{left:618px;bottom:374px;letter-spacing:0.12px;word-spacing:0.06px;}
#t22_160{left:618px;bottom:350px;letter-spacing:0.05px;word-spacing:0.13px;}
#t23_160{left:1154px;bottom:358px;}
#t24_160{left:618px;bottom:327px;letter-spacing:0.14px;word-spacing:0.04px;}
#t25_160{left:618px;bottom:304px;letter-spacing:-0.06px;word-spacing:0.25px;}
#t26_160{left:848px;bottom:312px;letter-spacing:-0.01px;}
#t27_160{left:871px;bottom:304px;letter-spacing:0.09px;word-spacing:0.09px;}
#t28_160{left:618px;bottom:281px;letter-spacing:0.12px;word-spacing:0.07px;}
#t29_160{left:618px;bottom:258px;letter-spacing:0.11px;word-spacing:-0.34px;}
#t2a_160{left:1110px;bottom:265px;}
#t2b_160{left:1121px;bottom:258px;letter-spacing:0.1px;}
#t2c_160{left:618px;bottom:234px;letter-spacing:0.08px;word-spacing:0.25px;}
#t2d_160{left:618px;bottom:211px;letter-spacing:0.06px;word-spacing:-0.06px;}
#t2e_160{left:618px;bottom:188px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t2f_160{left:766px;bottom:188px;}
#t2g_160{left:782px;bottom:188px;letter-spacing:0.19px;}
#t2h_160{left:618px;bottom:165px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2i_160{left:618px;bottom:141px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2j_160{left:764px;bottom:141px;}
#t2k_160{left:780px;bottom:141px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2l_160{left:618px;bottom:118px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2m_160{left:618px;bottom:95px;letter-spacing:0.16px;word-spacing:0.03px;}
#t2n_160{left:618px;bottom:72px;letter-spacing:0.11px;word-spacing:-0.7px;}
#t2o_160{left:1078px;bottom:79px;letter-spacing:-0.01px;}
#t2p_160{left:1101px;bottom:72px;letter-spacing:-0.05px;word-spacing:0.24px;}
#t2q_160{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_160{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_160{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_160{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_160{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_160{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_160{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_160{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s7_160{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_160{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts160" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg160Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg160" style="-webkit-user-select: none;"><object width="1210" height="935" data="160/160.svg" type="image/svg+xml" id="pdf160" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_160" class="t s0_160">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_160" class="t s1_160">© </span>
<span id="t3_160" class="t s0_160">(NCCN </span>
<span id="t4_160" class="t s1_160">© </span>
<span id="t5_160" class="t s0_160">), All rights reserved. NCCN Guidelines </span>
<span id="t6_160" class="t s1_160">® </span>
<span id="t7_160" class="t s0_160">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_160" class="t s2_160">NCCN Guidelines Version 4.2024 </span>
<span id="t9_160" class="t s2_160">Head and Neck Cancers </span>
<span id="ta_160" class="t s3_160">MS-19 </span>
<span id="tb_160" class="t s4_160">most extensively for reirradiation. </span>
<span id="tc_160" class="t s5_160">259 </span>
<span id="td_160" class="t s4_160">Careful anticipation of toxicity is </span>
<span id="te_160" class="t s4_160">especially important in planning the delivery of this modality to a patient. </span>
<span id="tf_160" class="t s4_160">SBRT has been delivered in conjunction with systemic therapy but caution </span>
<span id="tg_160" class="t s4_160">is advised due to the relatively limited experience with combining these </span>
<span id="th_160" class="t s4_160">modalities. </span>
<span id="ti_160" class="t s5_160">260 </span>
<span id="tj_160" class="t s6_160">Follow-up After RT </span>
<span id="tk_160" class="t s4_160">For patients whose cancer has been treated with RT, the recommended </span>
<span id="tl_160" class="t s4_160">follow-up (see </span><span id="tm_160" class="t s7_160">Follow-up Recommendations </span><span id="tn_160" class="t s4_160">in the NCCN Guidelines for </span>
<span id="to_160" class="t s4_160">Head and Neck Cancers) includes an assessment of thyroid function (ie, </span>
<span id="tp_160" class="t s4_160">the thyroid-stimulating hormone [TSH] level should be determined every </span>
<span id="tq_160" class="t s4_160">6–12 months) and surveillance-oriented physical examination, symptom </span>
<span id="tr_160" class="t s4_160">assessment and supportive care, and/or imaging as clinically indicated. </span>
<span id="ts_160" class="t s4_160">Increased TSH levels have been detected in 20% to 25% of patients who </span>
<span id="tt_160" class="t s4_160">have received neck irradiation. </span>
<span id="tu_160" class="t s5_160">261-263 </span>
<span id="tv_160" class="t s4_160">Changes in TSH may indicate thyroid </span>
<span id="tw_160" class="t s4_160">gland dysfunction or hypopituitarism if the skull base was irradiated. For </span>
<span id="tx_160" class="t s4_160">patients with signs or symptoms or who are at high risk for hypopituitarism, </span>
<span id="ty_160" class="t s4_160">screening laboratories may include growth hormone (GH), follicle- </span>
<span id="tz_160" class="t s4_160">stimulating hormone/luteinizing hormone (FSH/LH), free T4, insulin-like </span>
<span id="t10_160" class="t s4_160">growth factor 1 (IGF-1), thyroid-stimulating hormone (TSH), </span>
<span id="t11_160" class="t s4_160">adrenocorticotropic hormone (ACTH), and prolactin. </span>
<span id="t12_160" class="t s3_160">Systemic Therapy for Locally Advanced Squamous Cell Carcinoma </span>
<span id="t13_160" class="t s3_160">of the Head and Neck </span>
<span id="t14_160" class="t s4_160">Treatment that includes systemic therapy of H&amp;N cancers is </span>
<span id="t15_160" class="t s4_160">recommended for locoregionally advanced and metastatic disease. This </span>
<span id="t16_160" class="t s4_160">section describes systemic therapy for locally advanced SCCHN with </span>
<span id="t17_160" class="t s4_160">concurrent or sequential RT-based treatment. In patients with newly </span>
<span id="t18_160" class="t s4_160">diagnosed recurrent or metastatic SCCHN, testing for programmed death </span>
<span id="t19_160" class="t s4_160">ligand 1 (PD-L1) combined positive score (CPS) should be performed to </span>
<span id="t1a_160" class="t s4_160">guide treatment decisions, and next-generation sequencing (NGS) </span>
<span id="t1b_160" class="t s4_160">genomic profiling for biomarker identification of actionable alterations may </span>
<span id="t1c_160" class="t s4_160">be considered to guide treatment options. For detailed recommendations </span>
<span id="t1d_160" class="t s4_160">on combination and single-agent systemic therapy for metastatic (M1) </span>
<span id="t1e_160" class="t s4_160">disease (without surgery or RT treatment), see the section below under </span>
<span id="t1f_160" class="t s7_160">Very Advanced Head and Neck Cancers</span><span id="t1g_160" class="t s4_160">. Systemic therapy/RT for </span>
<span id="t1h_160" class="t s4_160">locoregionally advanced nasopharyngeal cancer is described below under </span>
<span id="t1i_160" class="t s7_160">Cancer of the Nasopharynx</span><span id="t1j_160" class="t s4_160">. </span>
<span id="t1k_160" class="t s6_160">Primary Systemic Therapy with Concurrent RT </span>
<span id="t1l_160" class="t s4_160">Randomized trials </span>
<span id="t1m_160" class="t s5_160">139,264-272 </span>
<span id="t1n_160" class="t s4_160">and meta-analyses </span>
<span id="t1o_160" class="t s5_160">273-277 </span>
<span id="t1p_160" class="t s4_160">showed significantly </span>
<span id="t1q_160" class="t s4_160">improved OS, DFS, and locoregional control when a systemic therapy and </span>
<span id="t1r_160" class="t s4_160">RT regimen (concomitant or, less commonly, sequential) was compared </span>
<span id="t1s_160" class="t s4_160">with RT alone for locally advanced disease. Limited data are available </span>
<span id="t1t_160" class="t s4_160">comparing the efficacy of different chemoradiotherapy regimens. </span>
<span id="t1u_160" class="t s4_160">High-dose cisplatin plus RT is the most studied effective systemic </span>
<span id="t1v_160" class="t s4_160">therapy/RT regimen and typically uses conventional fractionation or RT at </span>
<span id="t1w_160" class="t s4_160">2.0 Gy per fraction to 70 Gy administered over 7 weeks with concurrent </span>
<span id="t1x_160" class="t s4_160">cisplatin 100 mg/m </span>
<span id="t1y_160" class="t s5_160">2 </span>
<span id="t1z_160" class="t s4_160">given every 3 weeks for up to three doses. </span>
<span id="t20_160" class="t s5_160">151,264 </span>
<span id="t21_160" class="t s4_160">Because of perceived lower toxicity, low-dose once-a-week cisplatin has </span>
<span id="t22_160" class="t s4_160">been studied. A randomized phase III trial compared cisplatin 30 mg/m </span>
<span id="t23_160" class="t s5_160">2 </span>
<span id="t24_160" class="t s4_160">given once weekly to high-dose cisplatin, both given with RT to patients </span>
<span id="t25_160" class="t s4_160">with locally advanced SCCHN. </span>
<span id="t26_160" class="t s5_160">138 </span>
<span id="t27_160" class="t s4_160">The primary endpoint was locoregional </span>
<span id="t28_160" class="t s4_160">control. Most patients (93%) received study treatment in the adjuvant </span>
<span id="t29_160" class="t s4_160">setting. Locoregional control was inferior in the cisplatin 30 mg/m </span>
<span id="t2a_160" class="t s5_160">2 </span>
<span id="t2b_160" class="t s4_160">weekly </span>
<span id="t2c_160" class="t s4_160">arm compared to the high-dose cisplatin arm. The 2-year locoregional </span>
<span id="t2d_160" class="t s4_160">control rate was 58.5% in the weekly cisplatin arm and 73.1% in the high- </span>
<span id="t2e_160" class="t s4_160">dose cisplatin arm (</span><span id="t2f_160" class="t s7_160">P </span><span id="t2g_160" class="t s4_160">= .014). Acute toxicities of grade 3 or greater were </span>
<span id="t2h_160" class="t s4_160">less common in the weekly arm compared to the high-dose cisplatin arm </span>
<span id="t2i_160" class="t s4_160">(71.6% vs. 84.6%; </span><span id="t2j_160" class="t s7_160">P </span><span id="t2k_160" class="t s4_160">= .006). However, a systematic review and meta- </span>
<span id="t2l_160" class="t s4_160">analysis including six randomized studies with 554 patients with SCCHN </span>
<span id="t2m_160" class="t s4_160">showed that OS, PFS, and toxicity did not significantly differ between </span>
<span id="t2n_160" class="t s4_160">weekly cisplatin and high-dose cisplatin (both given with RT). </span>
<span id="t2o_160" class="t s5_160">278 </span>
<span id="t2p_160" class="t s4_160">Based on </span>
<span id="t2q_160" class="t s8_160">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
